{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T07:47:05Z","timestamp":1794988025036,"version":"4.9.1"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"S1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>Chronic migraine (CM) is a neurological disease characterized by frequent migraine attacks that prevent affected individuals from performing daily activities of living, significantly diminish quality of life, and increase familial burden. Before onabotulinumtoxinA was approved for CM, there were few treatment options for these seriously disabled patients and none had regulatory approval.<\/jats:p>\n          <jats:p>The terminology and recognition of CM evolved in parallel with the onabotulinumtoxinA clinical development program. Because there were no globally accepted classification criteria for CM when onabotulinumtoxinA was in development, the patient populations for the trials conducted by Allergan were determined by the Allergan migraine team in collaboration with headache scientists and clinicians. These trials and collaborations ultimately led to improvements in CM classifications.<\/jats:p>\n          <jats:p>In 2010, onabotulinumtoxinA became the first medication and first biologic approved specifically to prevent headaches in patients with CM. Approval was based on 2 similarly designed phase 3, double-blind, randomized, placebo-controlled, multicenter clinical studies. Both studies showed significantly greater improvements in mean change from baseline in headache-day frequency in patients with CM receiving onabotulinumtoxinA compared with those receiving placebo.<\/jats:p>\n          <jats:p>The safety and effectiveness of onabotulinumtoxinA have been established globally in &gt;5000 patients with CM with or without medication overuse treated in clinical and observational studies. Benefits also include improvements in quality of life, fewer psychiatric comorbidities, and reduced healthcare resource utilization. Across studies, onabotulinumtoxinA was well tolerated; adverse events tended to be mild or moderate in severity and to decline over subsequent treatment cycles.<\/jats:p>","DOI":"10.1097\/md.0000000000032600","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T19:00:59Z","timestamp":1690484459000},"page":"e32600","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact"],"prefix":"10.1097","volume":"102","author":[{"given":"Catherine C.","family":"Turkel","sequence":"first","affiliation":[{"name":"CCT Pharma Consulting, Newport Coast, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"Aurora","sequence":"additional","affiliation":[{"name":"Impel NeuroPharma, Inc., Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Dodick","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[{"name":"Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Silberstein","sequence":"additional","affiliation":[{"name":"Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F.","family":"Brin","sequence":"additional","affiliation":[{"name":"Allergan\/AbbVie, Irvine, CA, USA"},{"name":"University of California, Irvine, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20240803","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1468-2982.2009.01941.x","article-title":"Global prevalence of chronic migraine: a systematic review.","volume":"30","author":"Natoli","year":"2010","journal-title":"Cephalalgia"},{"key":"R3-20240803","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"390","year":"2017","journal-title":"Lancet"},{"issue":"Suppl 1","key":"R4-20240803","first-page":"A180","article-title":"Epidemiology of chronic daily headache in adolescents [abstract].","volume":"68","author":"Grosberg","year":"2007","journal-title":"Neurology"},{"key":"R5-20240803","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/nyas.12488","article-title":"Development of onabotulinumtoxinA for chronic migraine.","volume":"1329","author":"Whitcup","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"R6-20240803","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1523\/JNEUROSCI.0373-15.2015","article-title":"Migraine: multiple processes, complex pathophysiology.","volume":"35","author":"Burstein","year":"2015","journal-title":"J Neurosci"},{"key":"R7-20240803","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International Classification of Headache Disorders, 3rd edition.","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"key":"R8-20240803","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11916-011-0233-z","article-title":"Defining the differences between episodic migraine and chronic migraine.","volume":"16","author":"Katsarava","year":"2012","journal-title":"Curr Pain Headache Rep"},{"key":"R9-20240803","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/j.1526-4610.2012.02223.x","article-title":"Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study.","volume":"52","author":"Buse","year":"2012","journal-title":"Headache"},{"key":"R10-20240803","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/0333102414552532","article-title":"The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results.","volume":"35","author":"Manack Adams","year":"2015","journal-title":"Cephalalgia"},{"key":"R11-20240803","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/head.12999","article-title":"Chronic migraine: an update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies.","volume":"57","author":"Aurora","year":"2017","journal-title":"Headache"},{"key":"R12-20240803","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/head.12774","article-title":"Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine epidemiology and Outcomes (CaMEO) Study.","volume":"56","author":"Dodick","year":"2016","journal-title":"Headache"},{"key":"R13-20240803","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/0333102418821662","article-title":"CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.","volume":"39","author":"Dodick","year":"2019","journal-title":"Cephalalgia"},{"key":"R14-20240803","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1468-2982.2006.01172.x","article-title":"New appendix criteria open for a broader concept of chronic migraine.","volume":"26","author":"Olesen","year":"2006","journal-title":"Cephalalgia"},{"key":"R15-20240803","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/WNL.47.4.871","article-title":"Classification of daily and near-daily headaches: field trial of revised IHS criteria.","volume":"47","author":"Silberstein","year":"1996","journal-title":"Neurology"},{"key":"R16-20240803","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1526-4610.1982.hed2202066.x","article-title":"Transformation of episodic migraine into daily headache: analysis of factors.","volume":"22","author":"Mathew","year":"1982","journal-title":"Headache"},{"key":"R17-20240803","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1526-4610.1987.hed2702102.x","article-title":"Transformed or evolutive migraine.","volume":"27","author":"Mathew","year":"1987","journal-title":"Headache"},{"issue":"Suppl 7","key":"R18-20240803","first-page":"1","article-title":"Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society.","volume":"8","year":"1988","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"R19-20240803","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-2982.2003.00824.x","article-title":"Second Headache Classification Subcommittee The International Classification of Headache Disorders, 2nd ed.","volume":"24","author":"Olesen","year":"2004","journal-title":"Cephalalgia"},{"key":"R20-20240803","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1001\/archotol.1993.01880210108015","article-title":"Botulinum toxin for the treatment of hyperfunctional lines of the face.","volume":"119","author":"Blitzer","year":"1993","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"R21-20240803","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/s-2008-1064563","article-title":"Botulinum toxin A: a novel method to remove periorbital wrinkles.","volume":"10","author":"Keen","year":"1994","journal-title":"Facial Plast Surg"},{"key":"R22-20240803","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/00006534-199407000-00009","article-title":"Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study.","volume":"94","author":"Keen","year":"1994","journal-title":"Plast Reconstr Surg"},{"issue":"Suppl 2","key":"R23-20240803","first-page":"241","article-title":"Botulinum toxin type A (BTX-A) for migraine: an open label assessment [abstract P4-104].","volume":"13","author":"Binder","year":"1998","journal-title":"Mov Disord"},{"key":"R24-20240803","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1067\/mhn.2000.110960","article-title":"Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study.","volume":"123","author":"Binder","year":"2000","journal-title":"Otolaryngol Head Neck Surg"},{"key":"R25-20240803","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1526-4610.2000.00066.x","article-title":"Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.","volume":"40","author":"Silberstein","year":"2000","journal-title":"Headache"},{"key":"R26-20240803","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0333102418758283","article-title":"Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults.","volume":"38","author":"Tassorelli","year":"2018","journal-title":"Cephalalgia"},{"key":"R27-20240803","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jns.2013.05.003","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.","volume":"331","author":"Silberstein","year":"2013","journal-title":"J Neurol Sci"},{"key":"R28-20240803","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1186\/s40064-015-1386-8","article-title":"Does analgesic overuse matter? Response to onabotulinumtoxinA in patients with chronic migraine with or without medication overuse.","volume":"4","author":"Ahmed","year":"2015","journal-title":"SpringerPlus"},{"key":"R29-20240803","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"R30-20240803","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"R32-20240803","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1526-4610.2010.01678.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.","volume":"50","author":"Dodick","year":"2010","journal-title":"Headache"},{"key":"R33-20240803","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","article-title":"Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.","volume":"19","author":"Blumenfeld","year":"2018","journal-title":"J Headache Pain"},{"key":"R34-20240803","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10194-019-0976-1","article-title":"An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.","volume":"20","author":"Ahmed","year":"2019","journal-title":"J Headache Pain"},{"key":"R35-20240803","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/ene.13657","article-title":"Prospective real-world analysis of onabotulinumtoxinA in chronic migraine post-National Institute for Health and Care Excellence UK technology appraisal.","volume":"25","author":"Andreou","year":"2018","journal-title":"Eur J Neurol"},{"key":"R36-20240803","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/ene.13523","article-title":"OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study.","volume":"25","author":"Dominguez","year":"2018","journal-title":"Eur J Neurol"},{"key":"R37-20240803","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1129-2377-15-54","article-title":"Prospective analysis of the use of onabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.","volume":"15","author":"Khalil","year":"2014","journal-title":"J Headache Pain"},{"key":"R38-20240803","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s10194-016-0591-3","article-title":"A two years open-label prospective study of onabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.","volume":"17","author":"Negro","year":"2016","journal-title":"J Headache Pain"},{"key":"R39-20240803","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1186\/s40064-015-1636-9","article-title":"OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study.","volume":"4","author":"Negro","year":"2015","journal-title":"SpringerPlus"},{"key":"R40-20240803","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s10194-019-1030-z","article-title":"Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.","volume":"20","author":"Stark","year":"2019","journal-title":"J Headache Pain"},{"issue":"Suppl 1","key":"R41-20240803","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10072-018-3393-3","article-title":"OnabotulinumtoxinA for chronic migraine: a real-life Italian multicenter experience.","volume":"39","author":"Vernieri","year":"2018","journal-title":"Neurol Sci"},{"key":"R42-20240803","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s10194-016-0676-z","article-title":"Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.","volume":"17","author":"Vikelis","year":"2016","journal-title":"J Headache Pain"},{"key":"R43-20240803","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/ane.12171","article-title":"OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.","volume":"129","author":"Aurora","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"R44-20240803","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/jnnp-2013-307149","article-title":"Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.","volume":"86","author":"Silberstein","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 1","key":"R45-20240803","first-page":"27","article-title":"Efficacy and safety of onabotulinumtoxinA in an open-label study for the prophylactic treatment of chronic migraine in adult patients: COMPEL [abstract].","volume":"36","author":"Blumenfeld","year":"2016","journal-title":"Cephalalgia"},{"key":"R46-20240803","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jnnp-2018-319290","article-title":"Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety.","volume":"90","author":"Blumenfeld","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R47-20240803","doi-asserted-by":"crossref","first-page":"e027953","DOI":"10.1136\/bmjopen-2018-027953","article-title":"Cochrane systematic review and meta-analysis of botulinum toxin for the prevention of migraine.","volume":"9","author":"Herd","year":"2019","journal-title":"BMJ Open"},{"key":"R48-20240803","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.3390\/jcm10132898","article-title":"OnabotulinumtoxinA in migraine: a review of the literature and factors associated with efficacy.","volume":"10","author":"Ray","year":"2021","journal-title":"J Clin Med"},{"key":"R49-20240803","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40265-018-0894-6","article-title":"OnabotulinumtoxinA: a review in the prevention of chronic migraine.","volume":"78","author":"Frampton","year":"2018","journal-title":"Drugs"},{"key":"R50-20240803","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s10194-017-0784-4","article-title":"The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis.","volume":"18","author":"Matharu","year":"2017","journal-title":"J Headache Pain"},{"key":"R51-20240803","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0333102416652092","article-title":"OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: pooled results from the PREEMPT randomized clinical trial program.","volume":"36","author":"Lipton","year":"2016","journal-title":"Cephalalgia"},{"key":"R52-20240803","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1526-4610.2011.01990.x","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.","volume":"51","author":"Aurora","year":"2011","journal-title":"Headache"},{"key":"R53-20240803","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/head.13653","article-title":"FORWARD study: evaluating the comparative effectiveness of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine.","volume":"59","author":"Rothrock","year":"2019","journal-title":"Headache"},{"key":"R54-20240803","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/head.12456","article-title":"Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine.","volume":"54","author":"Rothrock","year":"2014","journal-title":"Headache"},{"key":"R55-20240803","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s10194-022-01492-y","article-title":"A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine.","volume":"23","author":"Khanal","year":"2022","journal-title":"J Headache Pain"},{"key":"R56-20240803","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/j.1526-4610.2009.01566.x","article-title":"A double-blind comparison of onabotulinumtoxin a (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study.","volume":"49","author":"Mathew","year":"2009","journal-title":"Headache"},{"key":"R57-20240803","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology.","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"R58-20240803","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mds.870020402","article-title":"Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.","volume":"2","author":"Brin","year":"1987","journal-title":"Mov Disord"},{"key":"R59-20240803","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpainsymman.2016.01.007","article-title":"OnabotulinumtoxinA improves pain in patients with post-stroke spasticity: findings from a randomized, double-blind, placebo-controlled trial.","volume":"52","author":"Wissel","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"R60-20240803","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pain.2006.09.012","article-title":"Exploding versus imploding headache in migraine prophylaxis with botulinum toxin A.","volume":"125","author":"Jakubowski","year":"2006","journal-title":"Pain"},{"key":"R61-20240803","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13849","article-title":"Mechanism of action of onabotulinumtoxinA in chronic migraine: a narrative review.","volume":"60","author":"Burstein","year":"2020","journal-title":"Headache"},{"key":"R62-20240803","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: a disorder of sensory processing.","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol Rev"},{"key":"R63-20240803","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1526-4610.2007.00969.x","article-title":"Concepts and mechanisms of migraine chronification.","volume":"48","author":"Bigal","year":"2008","journal-title":"Headache"},{"key":"R64-20240803","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/365160a0","article-title":"Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25.","volume":"365","author":"Blasi","year":"1993","journal-title":"Nature"},{"key":"R65-20240803","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: biology, pharmacology, and toxicology.","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol Rev"},{"key":"R66-20240803","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/head.13074","article-title":"Insights into the functional anatomy behind the PREEMPT injection paradigm: guidance on achieving optimal outcomes.","volume":"57","author":"Blumenfeld","year":"2017","journal-title":"Headache"},{"key":"R67-20240803","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3389\/fnhum.2016.00497","article-title":"Brain changes in responders vs. non-responders in chronic migraine: markers of disease reversal.","volume":"10","author":"Hubbard","year":"2016","journal-title":"Front Hum Neurosci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032600","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T01:56:22Z","timestamp":1722736582000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":65,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032600","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}